Positive
●
Proactive Investors
●
about 2 months ago
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) and Merck & Co Inc (NYSE:MRK, XETRA:6MK) said Wednesday their personalized mRNA cancer vaccine, intismeran, combined with Merck's Keytruda slowed melanoma recurrence and spread in a Phase 3 trial, in what would be the first randomized late-stage validation of a personalized neoantigen cancer vaccine. Moderna shares jumped 150% Wednesday morning, while Merck ...